You have full text access to this OnlineOpen article

Epidermoid anal cancer prognosis comparison among HIV+ and HIV− patients

  1. L. ABRAMOWITZ1,
  2. N. MATHIEU1,
  3. F. ROUDOT-THORAVAL2,
  4. N. LEMARCHAND3,
  5. P. BAUER4,
  6. C. HENNEQUIN5,
  7. E. MITRY6,
  8. C. ROMELAER3,
  9. T. APARICIO1,
  10. I. SOBHANI7

Article first published online: 17 APR 2009

DOI: 10.1111/j.1365-2036.2009.04026.x

Issue

Alimentary Pharmacology & Therapeutics

Alimentary Pharmacology & Therapeutics

Volume 30, Issue 4, pages 414–421, August 2009

Additional Information

How to Cite

ABRAMOWITZ, L., MATHIEU, N., ROUDOT-THORAVAL, F., LEMARCHAND, N., BAUER, P., HENNEQUIN, C., MITRY, E., ROMELAER, C., APARICIO, T. and SOBHANI, I. (2009), Epidermoid anal cancer prognosis comparison among HIV+ and HIV− patients. Alimentary Pharmacology & Therapeutics, 30: 414–421. doi: 10.1111/j.1365-2036.2009.04026.x

Author Information

  1. 1

    AP-HP, Service de gastroentérologie et Unité de proctologie medico-chirurgicale, Hôpital Universitaire Bichat, Paris, France

  2. 2

    AP-HP, Service de Santé Publique, Hôpital Henri Mondor, Université Paris, Créteil, France

  3. 3

    Service de proctologie, hôpital Leopold Bellan, Paris, France

  4. 4

    Service de proctologie medico-interventionnelle, Groupe Hôspitalier Diaconesse Croix Saint Simon, Paris, France

  5. 5

    AP-HP, Service de radiothérapie, Hôpital universitaire Saint Louis, Paris, France

  6. 6

    AP-HP, Service de gastroentérologie, Hôpital universitaire Ambroise Paré, Boulogne, France

  7. 7

    AP-HP, Université Paris 12, Service d’hépato-gastro-entérologie et oncologie; CHU Henri Mondor Créteil, Créteil, France

*Dr L. Abramowitz, Service de Gastroentérologie et Proctologie, Hôpital Universitaire Bichat Claude Bernard, 46 rue Henri Huchard, 75877 Paris, CEDEX 18, France. E-mail: laurent.abramowitz@bch.aphp.fr

Publication History

  1. Issue published online: 20 JUL 2009
  2. Article first published online: 17 APR 2009
  3. Publication data Submitted 11 March 2009 First decision 27 March 2009 Resubmitted 14 April 2009 Accepted 14 April 2009 Epub Accepted Article 15 April 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (157K)

Summary

Background  Previous studies suggest a poor prognosis of epidermoid anal cancer in HIV+ patients.

Aim  To investigate the long-term outcome of epidermoid anal cancer in HIV+ and HIV− patients in the highly active antiretroviral treatment (HAART) era.

Methods  We included all patients with epidermoid anal cancer referred to six hospitals from 1998 to 2004.

Results  In all, 151 patients (44 HIV+, 107 HIV−) were reviewed retrospectively for 27 (median of 16–44) months. HIV+ patients were male (100% vs. 27%, P < 0.001) and younger (45 vs. 62 years old, P < 0.001) than HIV− patients. No significant differences were observed in the tumour stage, pelvic radiotherapy dose or concomitant chemotherapy, according to the HIV status. After chemoradiotherapy, similar numbers of HIV+ and HIV− patients had grade III-IV toxicity. A complete response was obtained in 82% and 75% (N.S.) of cases, respectively. The disease-free survival rates were 77% and 67% (N.S.) and the overall survival rates were 85% and 84% (N.S.), respectively, after 3 years of follow-up. Duration of HIV infection, viral load and CD4 count had no effect on the survival rate of HIV+ patients with EAC.

Conclusions  The clinical outcome of HIV+ patients with epidermoid anal cancer is similar to that of HIV− patients. Therefore, the same therapeutic guidelines should be applied to both populations.

View Full Article (HTML) Get PDF (157K)